Meet the Advisory Board
Aditya Bardia, MD, MPH
Aditya Bardia, MD, MPH, is the Director of Translational Research Integration at UCLA Health Jonsson Comprehensive Cancer Center and Professor of Medicine at the Geffen School of Medicine. A leader in breast oncology, Dr. Bardia is known for pioneering research in antibody-drug conjugates, leading to the development of treatments like sacituzumab govitecan for metastatic triple-negative breast cancer. He has also advanced understanding of resistance mechanisms in cancer treatment. Dr. Bardia has received numerous awards for his research, including recognition from ASCO and the Mayo Clinic.
Hope S. Rugo, MD, FASCO
Hope S. Rugo, MD, FASCO, is a professor of medicine at UCSF Helen Diller Family Comprehensive Cancer Center, where she also serves as Director of Breast Oncology and Clinical Trials Education. Her research focuses on novel therapies for breast cancer and reducing treatment toxicity, with notable work on PARP inhibitors, immunotherapy, and scalp cooling for chemotherapy-induced hair loss. Dr. Rugo completed her medical training at the University of Pennsylvania and her fellowship at UCSF. She has received numerous awards for her clinical excellence and contributions to education, including recognition from the Cancer Care National Organization.
Kevin Kalinsky, MD, MS
Kevin Kalinsky, MD, MS, is the Director of the Glenn Family Breast Center at Winship Cancer Institute of Emory University and Associate Professor of Hematology and Medical Oncology. He focuses on early-phase clinical trials and personalized treatment strategies for breast cancer. His notable contributions include the RxPONDER trial, which helped refine the use of chemotherapy based on patients' recurrence scores. Dr. Kalinsky completed his medical training at the Medical University of South Carolina, with fellowships at Massachusetts General Hospital and Memorial Sloan Kettering.
Mark Burkard, MD, PhD
Mark Burkard, MD, PhD, is the Director of Holden Comprehensive Cancer Center at University of Iowa Health Care and Professor of Internal Medicine. He specializes in breast cancer and precision oncology, with a focus on genomic changes in cancer. Dr. Burkard has received several awards for his work in oncology and is known for his research on outlier patients who live long lives with metastatic breast cancer. He completed his medical and doctoral training at the University of Rochester, followed by a fellowship at Memorial Sloan Kettering Cancer Center.
Maryam Lustberg, MD, MPH
Maryam Lustberg, MD, MPH, is the Director of the Breast Center at Smilow Cancer Hospital and Chief of Breast Medical Oncology at Yale Cancer Center. Her research focuses on improving breast cancer outcomes through identifying biomarkers for treatment toxicity and recurrence, and she is an active investigator in national clinical trials. Dr. Lustberg is also a recognized clinician and mentor, receiving honors such as "Exceptional Women in Medicine" and participating in advocacy efforts for increasing patient engagement in clinical trials. She completed her medical degree and fellowship at The Ohio State University, where she also earned her MPH.